Total Payments
$509,743
2024 Payments
$127,646
Companies
47
Transactions
1,331
Medicare Patients
6,195
Medicare Billing
$2.7M
Payment Breakdown by Category
Other$373,696 (73.3%)
Consulting$62,029 (12.2%)
Travel$39,036 (7.7%)
Food & Beverage$32,010 (6.3%)
Research$2,917 (0.6%)
Education$54.96 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $342,563 | 157 | 67.2% |
| Consulting Fee | $62,029 | 24 | 12.2% |
| Travel and Lodging | $39,036 | 148 | 7.7% |
| Food and Beverage | $32,010 | 969 | 6.3% |
| Honoraria | $31,133 | 15 | 6.1% |
| Unspecified | $2,917 | 12 | 0.6% |
| Education | $54.96 | 6 | 0.0% |
Payments by Type
General
$506,826
1,319 transactions
Research
$2,917
11 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $275,596 | 252 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $115,466 | 283 | $0 (2024) |
| Blueprint Medicines Corporation | $38,392 | 52 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,282 | 79 | $0 (2024) |
| Grifols USA, LLC | $13,544 | 35 | $0 (2024) |
| F. Hoffmann-La Roche AG | $10,453 | 8 | $0 (2018) |
| Incyte Corporation | $7,421 | 11 | $0 (2024) |
| Amgen Inc. | $3,759 | 18 | $0 (2024) |
| BioCryst Pharmaceuticals, Inc. | $3,545 | 4 | $0 (2021) |
| GlaxoSmithKline, LLC. | $3,231 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,646 | 239 | Genentech USA, Inc. ($51,573) |
| 2023 | $53,478 | 183 | AstraZeneca Pharmaceuticals LP ($32,731) |
| 2022 | $21,298 | 148 | AstraZeneca Pharmaceuticals LP ($9,191) |
| 2021 | $35,806 | 106 | Genentech USA, Inc. ($26,818) |
| 2020 | $16,312 | 99 | Genentech USA, Inc. ($8,673) |
| 2019 | $102,350 | 184 | Genentech USA, Inc. ($70,608) |
| 2018 | $97,696 | 219 | Genentech USA, Inc. ($67,144) |
| 2017 | $55,157 | 153 | Genentech USA, Inc. ($40,284) |
All Payment Transactions
1,331 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,042.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $121.59 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $32.44 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $781.50 | General |
| 12/09/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $6.17 | General |
| 12/04/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $46.23 | General |
| 12/04/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: BIOLOGIC | ||||||
| 12/02/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,042.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/02/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,042.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $12.51 | General |
| Category: BIOLOGIC | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $109.66 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $16.88 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $493.96 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $222.38 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $150.14 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/07/2024 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $521.00 | General |
| 11/06/2024 | Genentech USA, Inc. | Xolair (Biological) | Travel and Lodging | In-kind items and services | $60.00 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $30.72 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | GlaxoSmithKline, LLC. | $1,584 | 8 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $509.00 | 1 |
| Trio Health APDS Registry | Pharming Healthcare, Inc. | $500.00 | 1 |
| CLOU064A2301,CLOU064A2302 | Novartis Pharmaceuticals Corporation | $324.09 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 1,633 | 22,642 | $2.2M | $695,283 |
| 2022 | 31 | 1,660 | 25,565 | $2.3M | $748,550 |
| 2021 | 33 | 1,737 | 25,512 | $2.3M | $707,920 |
| 2020 | 26 | 1,165 | 19,165 | $1.8M | $516,938 |
Total Patients
6,195
Total Services
92,884
Medicare Billing
$2.7M
Procedure Codes
119
All Medicare Procedures & Services
119 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 16 | 4,630 | $688,500 | $259,498 | 37.7% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 30 | 5,955 | $565,725 | $180,852 | 32.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 103 | 3,732 | $279,900 | $86,171 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 204 | 422 | $105,500 | $32,303 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 167 | 248 | $86,800 | $26,782 | 30.9% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 24 | 884 | $42,220 | $12,489 | 29.6% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 52 | 2,987 | $68,701 | $11,450 | 16.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 43 | 169 | $41,743 | $11,127 | 26.7% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 103 | 112 | $16,800 | $8,090 | 48.2% |
| 88189 | Flow cytometry technique for dna or cell analysis, 16 or more markers | Office | 2023 | 102 | 111 | $27,750 | $7,922 | 28.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $16,500 | $7,505 | 45.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 72 | 72 | $18,250 | $6,507 | 35.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 23 | 93 | $21,297 | $5,687 | 26.7% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 108 | 535 | $24,075 | $5,653 | 23.5% |
| 95044 | Test for allergy using skin patch | Office | 2023 | 15 | 1,096 | $20,824 | $5,389 | 25.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 23 | 266 | $39,900 | $5,122 | 12.8% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 26 | 26 | $7,800 | $3,634 | 46.6% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 71 | 95 | $9,500 | $3,274 | 34.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 36 | 64 | $11,008 | $3,186 | 28.9% |
| 95180 | Injection for rapid desensitization to allergen | Office | 2023 | 16 | 22 | $6,600 | $2,653 | 40.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 143 | $7,170 | $1,848 | 25.8% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 14 | 232 | $6,032 | $1,820 | 30.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 26 | 26 | $1,950 | $1,798 | 92.2% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 169 | 425 | $21,250 | $1,068 | 5.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 21 | 85 | $8,500 | $1,029 | 12.1% |
About Dr. Mark Scarupa, M.D
Dr. Mark Scarupa, M.D is a Allergy & Immunology healthcare provider based in Wheaton, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659303774.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Scarupa, M.D has received a total of $509,743 in payments from pharmaceutical and medical device companies, with $127,646 received in 2024. These payments were reported across 1,331 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($342,563).
As a Medicare-enrolled provider, Scarupa has provided services to 6,195 Medicare beneficiaries, totaling 92,884 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 119 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Wheaton, MD
- Active Since 07/07/2006
- Last Updated 10/23/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1659303774
Products in Payments
- Xolair (Biological) $287,406
- FASENRA (Drug) $51,664
- TEZSPIRE (Biological) $47,125
- AYVAKIT (Drug) $27,854
- Xembify (Biological) $13,328
- FASENRA (Biological) $12,846
- XOLAIR (Biological) $12,194
- OPZELURA (Drug) $7,421
- RUCONEST (Biological) $1,656
- Odactra (Drug) $1,597
- CUTAQUIG (Biological) $1,222
- DUPIXENT (Biological) $1,196
- Orladeyo (Drug) $1,164
- NUCALA (Biological) $1,143
- ORLADEYO (Drug) $877.71
- CUVITRU (Biological) $794.91
- Haegarda (Biological) $777.94
- Hizentra (Biological) $611.78
- XOLAIR (Drug) $565.78
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $495.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Wheaton
Dr. Martha White, M.d, M.D
Allergy & Immunology — Payments: $31,817
Allergy & Immunology $31,817
Dr. Michael Kaliner, M.d, M.D
Allergy & Immunology — Payments: $19,183
Allergy & Immunology $19,183
Athena Economides, M.d, M.D
Allergy & Immunology — Payments: $17,683
Allergy & Immunology $17,683
Dr. Michelle Crank, Md, MD
Allergy & Immunology — Payments: $8,814
Allergy & Immunology $8,814
Daniel Rosloff
Allergy & Immunology — Payments: $8,492
Allergy & Immunology $8,492